Loading clinical trials...

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

Clinical, Multi-centre, Randomised, Double-blind Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerized Extract of Parietaria Judaica Pollen on Patients With Hypersensitivity to This Pollen

NCT00916760•Laboratorios Leti, S.L.

View on ClinicalTrials.gov

Summary

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of Parietaria Judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

Detailed Description

Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo controlled study with two arms of treatment: placebo and active.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Informed consent, signed by the subject
•Positive clinical history of rhinitis/rhinoconjunctivitis allergy to Parietaria pollen
•Patient of both gender aged from 18 up to 55
•Diagnosed Sensitivity to Parietaria pollen base on:
•Positive Nasal provocation test Positive prick test to P. Judaica Specific IgE to P.Judaica \>0,7KU/L
•\- Patients who are able to comply with the dose regime

Exclusion Criteria

•Relevant sensitivity to another perenne allergen
•Patient with asthma
•Use of immunotherapy during the last four years
•Treatment with B. Blocking agents
•Patient suffering from some pathology in which adrenaline was contraindicated
•Subject suffers from a serious medical condition, which would interference the treatment and follow up of the subject in the study
•Subject suffers from autoimmune disease(thyroiditis, lupus, etc.)
•Conditions in which the patient can not offer full co-operation nad significant psychiatric disturbance.
•Intolerance to aspirin
•Pregnant women or with pregnancy risk and brest-feeding

Locations (11)

H. Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital Viladecans

Barcelona, Barcelona, Spain

Hospital Vega Baja

Alicante, Orihuela, Spain

H. de sagunto

Sagunto, Sagunto, Spain

Hospital General de Onteniente

Ontinyent, Valencia, Spain

Hospital Luis Alcañiz

Xàtiva, Valencia, Spain

Hospital Marina Baixa

Alicante, Spain

Hospital de Castellón

Castellon, Spain

Hospital Reina Sofía

Murcia, Spain

Hospital Virgen de la Arrixaca

Murcia, Spain

Key Dates

Start Date

February 1, 2008

Primary Completion Date

February 1, 2013

Completion Date

February 1, 2013

Last Updated

November 11, 2013

Enrollment

153

ACTUAL participants

Conditions

Allergic Rhinoconjunctivitis

Interventions

Depigoid Parietaria judaica 1000DPP/ml

BIOLOGICAL

Placebo

BIOLOGICAL

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT06778213

Allergic Rhinoconjunctivitis

View study

COMPLETEDPHASE2

Study of BLU-808 in Allergic Rhinoconjunctivitis

NCT06922448

Allergic Rhinoconjunctivitis

View study

COMPLETEDPHASE2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 11, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

Inclusion Criteria

Exclusion Criteria

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Study of BLU-808 in Allergic Rhinoconjunctivitis

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy